And only in the high HMOX1 signature arm, high PDL1 or PDL1‐positive arms, higher CD8+ cells arm, and higher tumor cell content arms, TKI + IO was more effective than TKI monotherapy. The gene discussed is CD8A; the disease is neoplasm.